Eta absorption by mesons

Using the $[SU(3)_{\mathrm{L}} \times SU(3)_{\mathrm{R}}]_{\mathrm{global}}\times [SU(3)_V]_{\mathrm{local}}$ chiral Lagrangian with hidden local symmetry, we evaluate the cross sections for the absorption of eta meson ($\eta$) by pion ($\pi$), rho ($\rho$), omega ($\omega$), kaon ($K$), and kaon star ($K^*$) in the tree-level approximation. With empirical masses and coupling constants as well as reasonable values for the cutoff parameter in the form factors at interaction vertices, we find that most cross sections are less than 1 mb, except the reactions $\rho\eta\to K\bar K^*(\bar KK^*)$, $\omega\eta\to K\bar K^*(\bar KK^*)$, $K^*\eta\to\rho K$, and $K^*\eta\to\omega K$, which are a few mb, and the reactions $\pi\eta\to K\bar K$ and $K\eta\to\pi K$, which are more than 10 mb. Including these reactions in a kinetic model based on a schematic hydrodynamic description of relativistic heavy ion collisions, we find that the abundance of eta mesons likely reaches chemical equilibrium with other hadrons in nuclear collisions at the Relativistic Heavy Ion Collider.Comment: 29 pages, 10 figures, version to appear in Nucl. Phys.

Modernization and Its Discontents

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/67022/2/10.1177_000276427702100208.pd

The new ALEPH Silicon Vertex Detector

The ALEPH collaboration, in view of the importance of effective vertex detection for the Higgs boson search at LEP 2, decided to upgrade the previous vertex detector. Main changes were an increased length (±20 cm), a higher granularity for rφ view (50 µm), a new preamplifier (MX7 rad hard chip), a polymide (upilex) fan-out on z side to carry the signals from the strips to the front-end electronics outside the fiducial region reducing consequently the passive material in the central region by a factor of two. The detector, the running experience and its performance will be described

The new ALEPH Silicon Vertex Detector

The ALEPH collaboration, in view of the importance of effective vertex detection for the Higgs boson search at LEP 2, decided to upgrade the previous vertex detector. Main changes were an increased length (±20 cm), a higher granularity for rφ view (50 µm), a new preamplifier (MX7 rad hard chip), a polymide (upilex) fan-out on z side to carry the signals from the strips to the front-end electronics outside the fiducial region reducing consequently the passive material in the central region by a factor of two. The detector, the running experience and its performance will be described

Incidence rates of narcolepsy diagnoses in Taiwan, Canada, and Europe: The use of statistical simulation to evaluate methods for the rapid assessment of potential safety issues on a population level in the SOMNIA study

BACKGROUND & OBJECTIVES: Vaccine safety signals require investigation, which may be done rapidly at the population level using ecological studies, before embarking on hypothesis-testing studies. Incidence rates were used to assess a signal of narcolepsy following AS03-adjuvanted monovalent pandemic H1N1 (pH1N1) influenza vaccination among children and adolescents in Sweden and Finland in 2010. We explored the utility of ecological data to assess incidence of narcolepsy following exposure to pandemic H1N1 virus or vaccination in 10 sites that used different vaccines, adjuvants, and had varying vaccine coverage.METHODS: We calculated incidence rates of diagnosed narcolepsy for periods defined by influenza virus circulation and vaccination campaign dates, and used Poisson regression to estimate incidence rate ratios (IRRs) comparing the periods during which wild-type virus circulated and after the start of vaccination campaigns vs. the period prior to pH1N1 virus circulation. We used electronic health care data from Sweden, Denmark, the United Kingdom, Canada (3 provinces), Taiwan, Netherlands, and Spain (2 regions) from 2003 to 2013. We investigated interactions between age group and adjuvant in European sites and conducted a simulation study to investigate how vaccine coverage, age, and the interval from onset to diagnosis may impact the ability to detect safety signals.RESULTS: Incidence rates of narcolepsy varied by age, continent, and period. Only in Taiwan and Sweden were significant time-period-by-age-group interactions observed. Associations were found for children in Taiwan (following pH1N1 virus circulation) and Sweden (following vaccination). Simulations showed that the individual-level relative risk of narcolepsy was underestimated using ecological methods comparing post- vs. pre-vaccination periods; this effect was attenuated with higher vaccine coverage and a shorter interval from disease onset to diagnosis.CONCLUSIONS: Ecological methods can be useful for vaccine safety assessment but the results are influenced by diagnostic delay and vaccine coverage. Because ecological methods assess risk at the population level, these methods should be treated as signal-generating methods and drawing conclusions regarding individual-level risk should be avoided

Viral capsids: Mechanical characteristics, genome packaging and delivery mechanisms

The main functions of viral capsids are to protect, transport and deliver their genome. The mechanical properties of capsids are supposed to be adapted to these tasks. Bacteriophage capsids also need to withstand the high pressures the DNA is exerting onto it as a result of the DNA packaging and its consequent confinement within the capsid. It is proposed that this pressure helps driving the genome into the host, but other mechanisms also seem to play an important role in ejection. DNA packaging and ejection strategies are obviously dependent on the mechanical properties of the capsid. This review focuses on the mechanical properties of viral capsids in general and the elucidation of the biophysical aspects of genome packaging mechanisms and genome delivery processes of double-stranded DNA bacteriophages in particular

Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment

Background: In 2010, a safety signal was detected for narcolepsy following vaccination with Pandemrix, an AS03-adjuvanted monovalent pandemic H1N1 influenza (pH1N1) vaccine. To further assess a possible association and inform policy on future use of adjuvants, we conducted a multi-country study of narcolepsy and adjuvanted pH1N1 vaccines. Methods: We used electronic health databases to conduct a dynamic retrospective cohort study to assess narcolepsy incidence rates (IR) before and during pH1N1 virus circulation, and after pH1N1 vaccination campaigns in Canada, Denmark, Spain, Sweden, Taiwan, the Netherlands, and the United Kingdom. Using a case-control study design, we evaluated the risk of narcolepsy following AS03- and MF59-adjuvanted pH1N1 vaccines in Argentina, Canada, Spain, Switzerland, Taiwan, and the Netherlands. In the Netherlands, we also conducted a case-coverage study in children born between 2004 and 2009. Results: No changes in narcolepsy IRs were observed in any periods in single study sites except Sweden and Taiwan; in Taiwan incidence increased after wild-type pH1N1 virus circulation and in Sweden (a previously identified signaling country), incidence increased after the start of pH1N1 vaccination. No association was observed for Arepanrix-AS03 or Focetria-MF59 adjuvanted pH1N1 vaccines and narcolepsy in children or adults in the case-control study nor for children born between 2004 and 2009 in the Netherlands case-coverage study for Pandemrix-AS03. Conclusions: Other than elevated narcolepsy IRs in the period after vaccination campaigns in Sweden, we did not find an association between AS03- or MF59-adjuvanted pH1N1 vaccines and narcolepsy in children or adults in the sites studied, although power to evaluate the AS03-adjuvanted Pandemrix brand vaccine was limited in our study

Computer microdensitometer (drum scanner) system. Period covered: April--June 1975

Non